Results 11 to 20 of about 62,547 (255)

Proton-pump inhibitors and risk of renal disease [PDF]

open access: yesJournal of Nephropharmacology, 2017
Proton pump inhibitors (PPIs) are one group of drugs that inhibit gastric acid secretion by binding irreversibly to the gastric proton pump to the gastric proton pump.
Mahrang Hedaiaty   +3 more
doaj   +1 more source

Risk of Bacterial Infection from Proton Pump Inhibitor Use

open access: yesThe Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2017
Currently, proton pump inhibitors are used in a wide range of patients with gastroesophageal reflux disease, peptic ulcer, and upper gastrointestinal symptoms such as dyspepsia.
Sung Soo Kim   +7 more
doaj   +1 more source

Association of Histamine-2 Blockers and Proton-Pump Inhibitors With Delirium Development in Critically Ill Adults: A Retrospective Cohort Study

open access: yesCritical Care Explorations, 2021
OBJECTIVES:. Histamine-2 receptor antagonists are commonly administered for stress ulcer prophylaxis in critically ill adults and may be associated with delirium development.
Ami Shiddapur, BS   +3 more
doaj   +1 more source

Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors

open access: yesGastroenterology Research and Practice, 2015
In 2006, hypomagnesemia was first described as a complication of proton-pump inhibitors. To address this issue, we systematically reviewed the literature.
Simone Janett   +7 more
doaj   +1 more source

Overuse of proton pump inhibitors [PDF]

open access: yesPolish Archives of Internal Medicine, 2015
Proton pump inhibitors (PPIs) are currently the most effective drugs inhibiting hydrochloric acid secretion. They have replaced histamine type 2 receptor antagonists in the majority of clinical indications, for example, functional dyspepsia, gastroesophageal reflux disease, or drug‑induced upper gastrointestinal tract injury.
Dorota, Ksiądzyna   +2 more
openaire   +2 more sources

ENDOSCOPIC AND HISTOPATHOLOGIC GASTRIC CHANGES IN CHRONIC USERS OF PROTON-PUMP INHIBITORS

open access: yesArquivos de Gastroenterologia, 2015
Background Proton-pump inhibitors have been used for at least two decades. They are among the most commonly sold drugs in the world. However, some controversy remains about the indications for their use and the consequences of their prolonged use ...
Sílvia Maria Perrone CAMILO   +5 more
doaj   +1 more source

Proton pump inhibitors and gastroenteritis [PDF]

open access: yesEuropean Journal of Epidemiology, 2016
An association between proton pump inhibitor (PPI) therapy and bacterial gastroenteritis has been suggested as well as contradicted. The aim of this study was to examine the association between the use of PPIs and occurrence of bacterial gastroenteritis in the prospective Rotterdam Study.
Hassing, Robert-Jan   +4 more
openaire   +2 more sources

Pharmacology of proton pump inhibitors [PDF]

open access: yesCurrent Gastroenterology Reports, 2008
The gastric H,K-ATPase is the primary target for the treatment of acid-related diseases. Proton pump inhibitors (PPIs) are weak bases composed of two moieties, a substituted pyridine with a primary pK(a) of about 4.0, which allows selective accumulation in the secretory canaliculus of the parietal cell, and a benzimidazole with a second pK(a) of about ...
Jai Moo, Shin, George, Sachs
openaire   +2 more sources

Risk of post-stroke pneumonia with proton pump inhibitors, H2 receptor antagonists and mucoprotective agents: A retrospective nationwide cohort study.

open access: yesPLoS ONE, 2019
Stroke patients are at high risk of developing pneumonia, which is major cause of post-stroke mortality. Proton pump inhibitors and H2 receptor antagonists are anti-ulcer drugs, which may predispose to the development of pneumonia by suppression of the ...
Tae-Jin Song, Jinkwon Kim
doaj   +1 more source

The impact of drug-drug interactions between proton pump inhibitors and metformin: A systematic review of clinical evidence [PDF]

open access: yesPharmacia
Metformin, a substrate of the organic cation transporters, is commonly co-prescribed with proton pump inhibitors, which inhibits these transporters. However, the clinical significance of this potential drug-drug interaction remains unclear.
Ria Andani Antong   +3 more
doaj   +3 more sources

Home - About - Disclaimer - Privacy